Programação do Evento

28/02/2026 - SÁBADO

HorárioTemaPalestrante
08:00 Welcome and Opening remarks (3 musketeers)
Session 1 - Welcome back!Chair - Erivelto Volpi
08:20 The centimeter mark or the intrathyroidal tumor. What’s the new cornerstone to define low-risk tumors?Michael Tuttle - USA
08:40 Defining the Suspicious Nodule accordingly to the new ATA GuidelinesLaura Boucai – USA
09:00 Personalizing Surgery for DTC: Integrating Theranostic Risk Stratification and Differentiation BiologySeza Gulec - USA
09:20 Q&A
09:30 Debate: Molecular Makers - Ricardo Gama X US and FBNAB as decision toolsChair: Evandro Vasconcelos
10:30 Break
10:50 Session 2 - The less aggressive approach to Low riskChair: Simone Dutenhefner
10:50 Any treatment necessary? How much treatment is enough?Erivelto Volpi
11:10 Isthmus carcinomas. Are we facing "the ugly" low-risk PTC?Michael Tuttle - USA
11:30 Nodal surgery in DTC preop assessmentGregory Randolph - USA
11:50 Defining Response to treatment of DTC using Thyroglobulin and Imaging - in accordance with the new ATA GuidelinesLaura Boucai – USA
12:10 Q&A
12:15 The Great Debate: Who Really Needs Surgery? (Lunch Session)
Afternoon SessionSession 3 - Who's afraid of Partial Thyroidectomy?
14:00 Micro MTC and LobectomyGabriele Materazzi – ITA
14:20 Lobectomy in “aggressive” variants of papillary carcinomaMichael Tuttle - USA
14:40 Lobectomy in follicular carcinoma and Oncocytic cell carcinomaMichael Yeh – USA
15:00 Revision surgery in DTC - who is a candidate?Gregory Randolph - USA
15:20 Q&A
15:30 Coffee Break
15:50 How Artificial Intelligence is Changing Thyroid Nodule DiagnosticsMichael Yeh - USA
Bread and butter for Thy Ca follow-upChair: Rafael Scheffel
16:20 What is the ideal TSH level after lobectomy? Why do we continue to use the same TSH range goal as before?Laura Boucai – USA
16:40 DTC Follow-up Strategy. What Really Matters in Lobectomy?
17:00 Is there an "exit ramp" of follow-up for the low-risk DTC patient after Lobectomy

01/03/2026 - DOMINGO

HorárioTemaPalestrante
Session 1 - Leading the U-turn in helpless casesCo-Chairs:
08:00 New medications on the block
08:20 Bring it back! (the redifferentiation strategy)
08:40 New approaches for anaplastic thyroid carcinoma
Session 2 - Intermediate Risk or the unexpected future high risk?Chair / Debater:
09:00 Prognostic factors not to miss the actual Intermediate RiskMichael Yeh - USA
09:20 Situations in which radioactive iodine can be the fundamental adjuvant
09:40 To what extent is surgical treatment decisive for the patient's cure?Gabriele Materazzi – ITA
10:00 Clinical follow-up and definition of disease in remission
10:20 Q&A
10:30 Coffee Break
Session 3 - Everyday pitfalls. Small doubts, big decisions.Chair / Debater:
11:00 What to do about high thyroglobulin levels when no visible disease is present
11:20 Dose less than 100 mCi. Does it still make sense in a world of lobectomies?
11:40 The New Era of RAI: Biology- and Dosimetry-Guided Therapy for Differentiated Thyroid CancerSeza Gulec – USA
12:30 Lunch Session
Session 4 - "Thyroidology in concert"Chair / Debater:
13:30 Neoadjuvant Therapies in Locally Advanced Invasive DTC.Gregory Randolph - USA
13:50 Active Surveillance of Cervical Lymph Nodes in Thyroid TumorsRafael Scheffel
14:10 Management of lymph node metastasis with ablative therapies
14:30 Tumor Board